Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2018 Filed May 17, 2018 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,051 | $138.11 | $145,153.61 |
DisclosureSEC source: 0001225208-18-009497 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,716.2823 Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,600 Underlying: Common Stock · 10,000 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,200 | $133.80 | $428,164.48 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · nonDerivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 58,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $133.43 to 134.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 800 | $134.69 | $107,751.04 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 61,985 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.51 to 134.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,200 | $133.79 | $1,097,110.80 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,767.2823 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $133.42 to 134.24. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,800 | $134.71 | $242,481.96 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,967.2823 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.51 to 134.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2018 Filed May 12, 2018 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $42.73 | $427,250.00 |
DisclosureSEC source: 0001225208-18-009211 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,767.2823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-007726 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 10,000 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,000 | $139.42 | $1,394,200.00 |
DisclosureSEC source: 0001225208-18-007726 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,767.2823 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,000 | $42.73 | $427,250.00 |
DisclosureSEC source: 0001225208-18-007726 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,767.2823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 01:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $134.78 | $539,120.00 |
DisclosureSEC source: 0001225208-18-007485 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 62,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,800 | $139.32 | $250,768.98 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · nonDerivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $138.72 to $139.65. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,200 | $138.05 | $165,662.04 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,408.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $137.57 to $138.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,200 | $139.95 | $167,939.04 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $139.72 to $140.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,100 | $136.45 | $150,095.99 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,808.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $136.05 to $136.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2018 Filed Mar 30, 2018 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-18-006838 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-003590 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $134.87 | $404,617.80 |
DisclosureSEC source: 0001225208-18-003590 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $134.52 to $135.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,799 | $134.15 | $241,333.51 |
DisclosureSEC source: 0001225208-18-003590 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $133.52 to $134.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 501 | $135.65 | $67,962.70 |
DisclosureSEC source: 0001225208-18-003590 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,407.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $135.56 to $135.72. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-18-003590 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 23:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,750 | $127.54 | $478,264.88 |
DisclosureSEC source: 0001225208-18-002789 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 66,785 F1 · price: This transaction was executed in multiple trades at prices ranging from $127.03 to $128.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-001949 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,200 | $127.22 | $661,548.16 |
DisclosureSEC source: 0001225208-18-001949 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $126.87 to $127.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $128.01 | $12,801.00 |
DisclosureSEC source: 0001225208-18-001949 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,808.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-18-001949 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-019215 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,206 | $113.86 | $365,029.39 |
DisclosureSEC source: 0001225208-17-019215 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F4 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $113.1750 to $114.16. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,094 | $114.41 | $239,582.71 |
DisclosureSEC source: 0001225208-17-019215 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,814.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $114.22 to $114.58. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-019215 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-017799 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,200 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,200 | $116.49 | $489,252.12 |
DisclosureSEC source: 0001225208-17-017799 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.90 to $116.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 800 | $117.25 | $93,800.00 |
DisclosureSEC source: 0001225208-17-017799 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,808.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $116.91 to $117.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $113.77 | $34,131.00 |
DisclosureSEC source: 0001225208-17-017799 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $113.65 to $113.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 29, 2017 Filed Nov 30, 2017 21:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-017799 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 21, 2017 Filed Nov 22, 2017 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-017589 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 70,535 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-016671 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,900 | $100.77 | $292,239.96 |
DisclosureSEC source: 0001225208-17-016671 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $100.21 to $101.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,400 | $101.53 | $243,676.32 |
DisclosureSEC source: 0001225208-17-016671 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,508.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $101.23 to $101.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 30, 2017 Filed Oct 30, 2017 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-016671 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-015648 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,800 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,200 | $108.85 | $566,038.20 |
DisclosureSEC source: 0001225208-17-015648 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $108.30 to $109.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $109.34 | $10,934.00 |
DisclosureSEC source: 0001225208-17-015648 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,808.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-015648 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,300 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-17-014419 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock · 5,300 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,300 | $112.15 | $594,401.36 |
DisclosureSEC source: 0001225208-17-014419 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $111.78 to $112.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,300 | $44.62 | $236,459.50 |
DisclosureSEC source: 0001225208-17-014419 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,908.1926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2017. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,000 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-17-013379 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,800 Underlying: Common Stock · 25,000 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it includes 60,479 shares previously owned directly which are now owned by trust. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 25,000 | $116.00 | $2,900,037.50 |
DisclosureSEC source: 0001225208-17-013379 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP, Heart Valve Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,608.1926 F2 · price: This transaction was executed in multiple trades at prices ranging from $116.00 to $116.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person; and it includes 60,479 shares previously owned directly which are now owned by trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.